278 related articles for article (PubMed ID: 24343001)
1. Effect of the coadministration of daclatasvir on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate.
Bifano M; Sevinsky H; Hwang C; Kandoussi H; Jiang H; Grasela D; Bertz R
Antivir Ther; 2014; 19(5):511-9. PubMed ID: 24343001
[TBL] [Abstract][Full Text] [Related]
2. Lack of a clinically important pharmacokinetic interaction between sofosbuvir or ledipasvir and hormonal oral contraceptives norgestimate/ethinyl estradiol in HCV-uninfected female subjects.
German P; Moorehead L; Pang P; Vimal M; Mathias A
J Clin Pharmacol; 2014 Nov; 54(11):1290-8. PubMed ID: 24925712
[TBL] [Abstract][Full Text] [Related]
3. Influence of alitretinoin on the pharmacokinetics of the oral contraceptive ethinyl estradiol/norgestimate.
Schmitt-Hoffmann AH; Roos B; Sauer J; Schleimer M; Schoetzau A; Leese PT; Weidekamm E; Maares J
Clin Exp Dermatol; 2011 Apr; 36 Suppl 2():4-11. PubMed ID: 21443598
[TBL] [Abstract][Full Text] [Related]
4. The effect of efavirenz on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy HIV-negative women.
Sevinsky H; Eley T; Persson A; Garner D; Yones C; Nettles R; Krantz K; Bertz R; Zhang J
Antivir Ther; 2011; 16(2):149-56. PubMed ID: 21447863
[TBL] [Abstract][Full Text] [Related]
5. The effect of atazanavir/ritonavir on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy women.
Zhang J; Chung E; Yones C; Persson A; Mahnke L; Eley T; Xu X; Bertz R
Antivir Ther; 2011; 16(2):157-64. PubMed ID: 21447864
[TBL] [Abstract][Full Text] [Related]
6. Effect of laropiprant, a PGD2 receptor 1 antagonist, on estradiol and norgestimate pharmacokinetics after oral contraceptive administration in women.
Schwartz JI; Liu F; Wang YH; Pramanik B; Johnson-Levonas AO; Gutierrez MJ; Lai E; Wagner JA
Am J Ther; 2009; 16(6):487-95. PubMed ID: 19940609
[TBL] [Abstract][Full Text] [Related]
7. Effect of saxagliptin on the pharmacokinetics of the active components of Ortho-Cyclen(®), a combined oral contraceptive containing ethinyl estradiol and norgestimate, in healthy women.
Upreti VV; Hsiang CB; Li L; Xu X; LaCreta FP; Boulton DW
Diabetes Obes Metab; 2012 Dec; 14(12):1155-7. PubMed ID: 22776778
[TBL] [Abstract][Full Text] [Related]
8. Lack of effect of tenofovir disoproxil fumarate on pharmacokinetics of hormonal contraceptives.
Kearney BP; Mathias A
Pharmacotherapy; 2009 Aug; 29(8):924-9. PubMed ID: 19637945
[TBL] [Abstract][Full Text] [Related]
9. A Multi-Center, Open-Label, Pharmacokinetic Drug Interaction Study of Erenumab and a Combined Oral Contraceptive in Healthy Females.
Xu Y; Gabriel K; Wang Y; Zhou Y; Eisele O; Vutikullird A; Mikol DD; Lee E
CNS Drugs; 2019 May; 33(5):513-522. PubMed ID: 30963506
[TBL] [Abstract][Full Text] [Related]
10. Cycle control, tolerability, and satisfaction among women switching from 30-35 microg ethinyl estradiol-containing oral contraceptives to the triphasic norgestimate/25 microg ethinyl estradiol-containing oral contraceptive Ortho Tri-Cyclen LO.
Poindexter AN; Burkman R; Fisher AC; LaGuardia KD
Int J Fertil Womens Med; 2003; 48(4):163-72. PubMed ID: 13677549
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris.
Lucky AW; Henderson TA; Olson WH; Robisch DM; Lebwohl M; Swinyer LJ
J Am Acad Dermatol; 1997 Nov; 37(5 Pt 1):746-54. PubMed ID: 9366821
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Potential Drug-Drug Interaction Between Delayed-Release Dimethyl Fumarate and a Commonly Used Oral Contraceptive (Norgestimate/Ethinyl Estradiol) in Healthy Women.
Zhu B; Nestorov I; Zhao G; Meka V; Leahy M; Kam J; Sheikh SI
Clin Pharmacol Drug Dev; 2017 Nov; 6(6):604-613. PubMed ID: 28783872
[TBL] [Abstract][Full Text] [Related]
13. Clinical experience with a new norgestimate-containing oral contraceptive.
Huber J
Int J Fertil; 1991; 36 Suppl 1():25-31. PubMed ID: 1678378
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic overview of Ortho Evra/Evra.
Abrams LS; Skee D; Natarajan J; Wong FA
Fertil Steril; 2002 Feb; 77(2 Suppl 2):S3-12. PubMed ID: 11849630
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of a transdermal contraceptive patch and an oral contraceptive.
Devineni D; Skee D; Vaccaro N; Massarella J; Janssens L; LaGuardia KD; Leung AT
J Clin Pharmacol; 2007 Apr; 47(4):497-509. PubMed ID: 17389559
[TBL] [Abstract][Full Text] [Related]
16. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
Jick SS; Kaye JA; Russmann S; Jick H
Contraception; 2006 Mar; 73(3):223-8. PubMed ID: 16472560
[TBL] [Abstract][Full Text] [Related]
17. Comparison of a novel norgestimate/ethinyl estradiol oral contraceptive (Ortho Tri-Cyclen Lo) with the oral contraceptive Loestrin Fe 1/20.
Hampton RM; Short M; Bieber E; Bouchard C; Ayotte N; Shangold G; Fisher AC; Creasy GW
Contraception; 2001 Jun; 63(6):289-95. PubMed ID: 11672549
[TBL] [Abstract][Full Text] [Related]
18. Influence of taranabant, an orally active, highly selective, potent cannabinoid-1 receptor (CB1R) inverse agonist, on ethinyl estradiol and norelgestromin plasma pharmacokinetics.
Schwartz JI; Dunbar S; Yuan J; Li S; Miller DL; Rosko K; Johnson-Levonas AO; Lasseter KC; Wagner JA
J Clin Pharmacol; 2009 Jan; 49(1):72-9. PubMed ID: 18936284
[TBL] [Abstract][Full Text] [Related]
19. Absence of effect of oral rifaximin on the pharmacokinetics of ethinyl estradiol/norgestimate in healthy females.
Trapnell CB; Connolly M; Pentikis H; Forbes WP; Bettenhausen DK
Ann Pharmacother; 2007 Feb; 41(2):222-8. PubMed ID: 17284510
[TBL] [Abstract][Full Text] [Related]
20. Effect of raltegravir on estradiol and norgestimate plasma pharmacokinetics following oral contraceptive administration in healthy women.
Anderson MS; Hanley WD; Moreau AR; Jin B; Bieberdorf FA; Kost JT; Wenning LA; Stone JA; Wagner JA; Iwamoto M
Br J Clin Pharmacol; 2011 Apr; 71(4):616-20. PubMed ID: 21395656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
